Table 1. Baseline clinical and demographic characteristics.
| Total Population N = 432 |
SVR12 N = 404 |
No SVR12 N = 28 |
P-valuea | |
|---|---|---|---|---|
| Age (years), mean ± SD | 55.7±9.7 | 55.3±9.2 | 51.7±9.4 | 0.039 |
| Gender, n (%) | 0.561 | |||
| Male | 335 (77.5%) | 312 (77.2%) | 23 (82.1%) | |
| Female | 96 (22.2%) | 91 (22.5%) | 5 (17.8%) | |
| Unknown | 1 (0.2%) | 1 (0.3%) | 0 (0.0%) | |
| Ethnicity, n (%) | 0.101 | |||
| Black | 236 (54.6%) | 225 (55.7%) | 11 (39.3%) | |
| White | 101 (23.4%) | 90 (22.3%) | 11 (39.3%) | |
| Hispanic | 73 (16.9%) | 67 (16.6%) | 6 (21.4%) | |
| Unknown | 22 (5.1%) | 22 (5.5%) | 0 (0.0%) | |
| Insurance Type, n (%) | 0.587 | |||
| Commercial | 54 (12.5%) | 51 (12.6%) | 3 (10.7%) | |
| Medicaid | 148 (34.3%) | 136 (33.7%) | 12 (42.9%) | |
| Medicare | 81 (18.7%) | 78 (19.3%) | 3 (10.7%) | |
| Self-pay | 13 (3.0%) | 13 (3.2%) | 0 (0.0%) | |
| Other or unknown | 136 (31.4%) | 126 (31.2%) | 10 (35.7%) | |
| Geographic Region, n (%) | 0.819 | |||
| Northeast | 193 (44.7%) | 179 (44.3%) | 14 (50.0%) | |
| Midwest | 150 (34.7%) | 142 (35.2%) | 8 (28.6%) | |
| South | 84 (19.4%) | 78 (19.3%) | 6 (21.4%) | |
| West | 5 (1.2%) | 5 (1.2%) | 0 (0.0%) | |
| BMIb, n (%) | 0.893 | |||
| Underweight: <18.5 | 8 (1.8%) | 8 (2.4%) | 0 (0.0%) | |
| Normal weight: 18.5 to 24.9 | 168 (28.9%) | 156 (46.0%) | 12 (48.0%) | |
| Overweight: > 25.0 to 29.9 | 103 (23.8%) | 96 (28.3%) | 7 (28.0%) | |
| Obese: ≥30 | 85 (19.7%) | 79 (23.3%) | 6 (24.0%) | |
| Unknown | 68 (15.7%) | 65 (16.1%) | 3 (10.7%) | |
| Genotype, n (%) | ||||
| Not genotyped | 2 (0.5%) | 2 (0.5%) | 0 (0.0%) | 0.713 |
| Genotyped | ||||
| GT1Ac | 275 (63.7%) | 256 (63.4%) | 19 (67.9%) | 0.936 |
| GT1B | 92 (21.2%) | 87 (21.5%) | 5 (17.9%) | |
| GT1X | 7 (1.6%) | 6 (1.5%) | 1 (3.6%) | |
| GT2 | 25 (5.8%) | 23 (5.7%) | 2 (7.1%) | |
| GT3 | 27 (6.3%) | 26 (6.4%) | 1 (3.6%) | |
| GT4 | 4 (0.9%) | 4 (1.0%) | 0 (0.0%) | |
| Baseline Labs | ||||
| CD4 count, n (%) | 325 (75.2%) | 303 (75.0%) | 22 (78.6%) | 0.826 |
| CD4 count <200 cells/ mm3, n (%) | 27 (6.3%) | 24 (7.9%) | 3 (13.6%) | 0.035 |
| Initial HCV VLd, n (%) | 358 (82.9%) | 334 (82.7%) | 24 (85.7%) | 0.128 |
| HCV VL <800K IU/ML | 92 (21.3%) | 90 (27.0%) | 2 (8.3%) | 0.021 |
| HCV VL 800K-6MM IU/ML | 210 (48.6%) | 193 (57.8%) | 17 (70.8%) | |
| HCV VL >6MM IU/ML | 56 (12.9%) | 51 (15.3%) | 5 (20.8%) | |
| HIV VL, n (%) | 357 (82.6%) | 334 (82.7%) | 23 (82.1%) | 0.701 |
| HIV VL <200 copies/ML, n (%) | 336 (77.8%) | 315 (94.3%) | 21 (91.3%) | 0.553 |
| ALTe, n (%) | 349 (80.8%) | 324 (80.2%) | 25 (89.2%) | 0.611 |
| ALT (IU/L), mean ± SD | 62.1±62.8 | 59.5±59.2 | 83.9±77.6 | 0.012 |
| ALT >55 IU/L, n (%) | 118 (27.3%) | 106 (26.2%) | 12(42.9%) | 0.001 |
| ASTf, n (%) | 342 (79.2%) | 319 (78.9%) | 23 (82.1%) | 0.419 |
| AST (IU/L), mean ± SD | 60.5±53.4 | 54.9±37.0 | 89.5±78.9 | 0.019 |
| AST >48 IU/L, n (%) | 144 (33.3%) | 129 (31.9%) | 15 (53.6%) | 0.037 |
| Total Bilirubin, n (%) | 349 (80.8%) | 324 (80.2%) | 25 (89.2%) | 0.621 |
| Total Bilirubin (mg/DL), mean ± SD | 0.9±1.1 | 0.7±0.6 | 1.1±1.4 | 0.512 |
| Total Bilirubin >1.2 mg/DL, n (%) | 45 (10.4%) | 40 (9.9%) | 5 (17.8%) | 0.022 |
| FIB-4g n, (%) | 334 (11.1%) | 312 (77.2%) | 22 (78.5%) | 0.712 |
| FIB-4 < 1.45 | 92 (21.3%) | 89 (28.5%) | 3 (13.6%) | 0.012 |
| FIB-4 1.45to ≤ 3.25 | 161 (37.3%) | 151 (48.4%) | 10 (45.5%) | |
| FIB-4 > 3.25 | 81 (18.8%) | 72 (23.1%) | 9 (40.9%) | |
| Comorbidities, n (%) | ||||
| Asthma | 62 (14.4%) | 59 (14.6%) | 3 (10.7%) | 0.570 |
| Cancer | 32 (7.4%) | 28 (6.9%) | 4 (14.3%) | 0.016 |
| Cirrhosis | 100 (23.1%) | 89 (22.0%) | 11 (40.7%) | 0.026 |
| Depression | 148 (34.3%) | 134 (33.1%) | 14 (50.0%) | 0.039 |
| Diabetes | 59 (13.6%) | 53 (13.1%) | 6 (21.4%) | 0.022 |
| Heart Disordersh | 68 (15.7%) | 67 (16.6%) | 1 (3.6%) | 0.016 |
| Hepatitis B Infection | 11 (2.5%) | 9 (2.2%) | 2 (7.1%) | 0.031 |
| Hypertension | 186 (43.1%) | 173 (42.8%) | 13 (46.4%) | 0.709 |
| Hyperlipidemia | 76 (17.6%) | 72 (17.8%) | 4 (14.3%) | 0.635 |
| Chronic kidney disease | 53 (12.2%) | 48 (11.9%) | 5 (17.9%) | 0.035 |
| Liver transplant recipient | 1 (0.2%) | 0 (0.0%) | 1 (3.6%) | 0.065 |
| Psychiatric Disorders | 87 (20.1%) | 81 (20.1%) | 6 (21.4%) | 0.860 |
| Substance abuse | 157 (36.3%) | 141 (34.9%) | 16 (57.1%) | 0.018 |
| Tobacco use | 199 (46.1%) | 183 (45.3%) | 16 (57.1%) | 0.022 |
| DAA Therapies | 0.001 | |||
| + RBVi, n (%) | 70 (16.2%) | 59 (14.6%) | 11 (39.3%) | |
| - RBV, n (%) | 362 (83.8%) | 345 (85.4% | 17 (60.7%) |
a P-value <0.05 was considered statistically significant.
b BMI = body mass index.
c GT = genotype.
d VL = viral load.
e ALT = alanine aminotransferase.
f AST = aspartate aminotransferase.
g FIB-4 = fibrosis-4 score for liver.
h Heart disorders = cardiovascular disease, coronary artery disease, aortic aneurysm.
i RBV = ribavirin.